Our Biostatistics services form the backbone of successful clinical trials and drug development programs, transforming complex data into meaningful insights. As a full-service Contract Research Organization (CRO), we provide expert statistical support to ensure the scientific integrity, regulatory compliance, and success of your clinical research.
Explore MoreOur Laboratory Services are designed to deliver high-quality, timely, and accurate data that supports your clinical trials and drug development programs. As a full-service Contract Research Organization (CRO), we offer cutting-edge laboratory solutions tailored to meet your specific needs across a range of therapeutic areas.
Explore MoreAt GGAC Research, safety comes first. As a full-service Contract Research Organization (CRO), we provide comprehensive Clinical Safety & Pharmacovigilance solutions to ensure the well-being of participants and compliance with global safety standards throughout the lifecycle of your product.
Explore Morewe recognize that clinical trials demand vigilant oversight to ensure participant safety, data accuracy, and protocol adherence. Our Medical Monitoring solutions are a cornerstone of our full-service Contract Research Organization (CRO) offerings, providing real-time expert guidance and oversight to support the success of your clinical trials.
Explore MoreAt GGAC Research, we turn your innovative ideas into transformative therapies. As a trusted full-service Contract Research Organization (CRO), we offer comprehensive Drug Development solutions that take your product from concept to market with precision, efficiency, and compliance.
Explore MoreAs a full-service Contract Research Organization (CRO), our Clinical Trial Management solutions are designed to streamline every phase of your clinical research journey, ensuring efficiency, compliance, and impactful outcomes.
Explore More
As a CRO with a deep commitment to neurodegenerative disease research, GGAC Research has been instrumental in advancing the development of Albrioza. Through its expertise in clinical trial management, regulatory affairs, and biostatistics, GGAC has provided the critical infrastructure needed to propel this innovative therapy forward.
+ Read More
Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disorder, continues to challenge researchers and clinicians worldwide. As one of the few FDA-approved treatments, Rilutek (riluzole) has long been a cornerstone therapy, offering modest extensions in survival for ALS patients. However, GGAC Research has embarked on a transformative journey to amplify the efficacy of Rilutek and redefine its role in combating ALS.
+ Read More
GGAC Research has established itself as a global leader in the fight against ALS. Their unwavering dedication to understanding the mechanisms of the disease and developing groundbreaking treatments has earned them a reputation for excellence in clinical research. By collaborating with leading pharmaceutical companies, academic institutions, and patient advocacy groups, GGAC Research ensures a multidisciplinary approach to ALS drug development.
+ Read More